Form 4: Mangoceuticals Director Kenny Myers Reports Acquisition and Disposal of Shares

Director Kenny Myers reports acquiring 25,000 shares of Mangoceuticals common stock as a bonus and disposing of 36,667 shares.

Summary

• Kenny Myers, a director of Mangoceuticals, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On April 10, 2025, Myers acquired 25,000 shares of common stock as a discretionary bonus for services rendered as a board member.
• The acquisition was made under the company's Second Amended and Restated 2022 Equity Incentive Plan and is exempt under Rule 16b-3.
• On the same day, Myers disposed of 36,667 shares.
• Following these transactions, Myers's beneficially owned shares are not specified in the document.

Sentiment

Score: 5

Explanation: The document presents a neutral view as it simply reports transactions. The acquisition is a positive, but the disposal tempers the sentiment.

Positives

• The acquisition of shares as a bonus indicates the company's recognition of the director's services.

Negatives

• The disposal of 36,667 shares by the director could be interpreted negatively by the market.

Risks

• The document does not provide a clear picture of the director's total holdings after the reported transactions, making it difficult to assess the overall impact.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The transactions could influence investor sentiment regarding the company's stock.

Key Dates

Keywords

Form 4, beneficial ownership, MGRX, Mangoceuticals, director, Kenny Myers, equity incentive plan, shares, acquisition, disposal